150 related articles for article (PubMed ID: 18077312)
1. Comment on: Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Collazos J
J Antimicrob Chemother; 2008 Feb; 61(2):466-7; author reply 467. PubMed ID: 18077312
[No Abstract] [Full Text] [Related]
2. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
3. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
Borrelli P; Imperato A; Murdaca G; Scudeletti M
Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
[TBL] [Abstract][Full Text] [Related]
7. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
[No Abstract] [Full Text] [Related]
9. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
Lopez Dupla M; Gil Aguado A; Lavilla Uriol P; Pintado Garcia V; Valencia Ortega E; Martinez Martinez P; Garcia-Puig J
J Antimicrob Chemother; 1993 Oct; 32(4):657-9. PubMed ID: 8288512
[No Abstract] [Full Text] [Related]
10. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
11. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
[No Abstract] [Full Text] [Related]
12. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus.
Laguna F; Torre-Cisneros J; Moreno V; Villanueva JL; Valencia E
Clin Infect Dis; 1995 Sep; 21(3):711-2. PubMed ID: 8527591
[No Abstract] [Full Text] [Related]
13. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL
Clin Infect Dis; 1995 Jan; 20(1):191. PubMed ID: 7727652
[No Abstract] [Full Text] [Related]
14. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.
Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T
Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683
[No Abstract] [Full Text] [Related]
15. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
16. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
[TBL] [Abstract][Full Text] [Related]
18. [Clinical signs of visceral leishmaniasis in adults: is the manner of presentation changing?].
Gaeta GB
Parassitologia; 2004 Jun; 46(1-2):225-6. PubMed ID: 15305722
[TBL] [Abstract][Full Text] [Related]
19. An unwelcome synergy: leishmaniasis and HIV.
Colasanti J; Altamirano J; Espinoza L
Am J Med; 2013 Feb; 126(2):114-6. PubMed ID: 23331437
[No Abstract] [Full Text] [Related]
20. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.
Calza L; D'Antuono A; Marinacci G; Manfredi R; Colangeli V; Passarini B; Orioli R; Varoli O; Chiodo F
J Am Acad Dermatol; 2004 Mar; 50(3):461-5. PubMed ID: 14988693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
